Get the Stockscreener App
41.65
1.69%
0.93
Moderna Inc stock is traded at $41.65, with a volume of 5.77M.
It is up +1.69% in the last 24 hours and up +5.15% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$40.72
Open:
$41.4
24h Volume:
5.77M
Relative Volume:
0.61
Market Cap:
$15.67B
Revenue:
$5.06B
Net Income/Loss:
$-2.22B
P/E Ratio:
-7.1564
EPS:
-5.82
Net Cash Flow:
$-3.96B
1W Performance:
-2.31%
1M Performance:
+5.15%
6M Performance:
-65.15%
1Y Performance:
-59.59%
1-Day Range:
$39.88
$42.54
1-Week Range:
$39.88
$45.40
52-Week Range:
$31.94
$170.47
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
41.59 | 15.67B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.79 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.51 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
663.38 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.34 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.33 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Up More Than 500% in 12 Months, Is It Too Late to Buy Summit Therapeutics Stock? - The Motley Fool
Why Moderna (MRNA) Crashed on Wednesday? - Yahoo Finance
S&P 500 Gains and Losses Today: Moderna Stock Plunges After Analyst Downgrade - MSN
Decoding Moderna's Options Activity: What's the Big Picture? - Benzinga
Moderna Shares Fall After TD Cowen Cuts Price Target -January 29, 2025 at 02:55 pm EST - Marketscreener.com
As bird flu becomes a growing threat, Moderna is awarded $590M to develop mRNA pandemic influenza vaccines - AOL
Why MRNA Stock Is Retreating - Yahoo Finance
Moderna Stock Is Sliding Wednesday: Here's Why - Benzinga
Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry. - MSN
Moderna stock drops as Goldman Sachs cuts rating By Investing.com - Investing.com Canada
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Moderna Stock Falls on Vaccine Revenue Concerns - Schaeffers Research
Moderna’s stock is falling. Goldman Sachs says it’s no longer a buy. - MarketWatch
Moderna down as Goldman Sachs downgrades on revenue outlook - MSN
Moderna stock down as Goldman Sachs downgrades (MRNA:NASDAQ) - Seeking Alpha
Moderna (NASDAQ:MRNA) Lowered to "Neutral" Rating by The Goldman Sachs Group - MarketBeat
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025 - Joplin Globe
Analyst recommendations: At&T, Caterpillar, Coinbase, Verizon, Moderna… - Marketscreener.com
Goldman Sachs Downgrades Moderna to Neutral From Buy, Adjusts Price Target to $51 From $99 - Marketscreener.com
Moderna (NASDAQ:MRNA) Price Target Cut to $99.00 by Analysts at The Goldman Sachs Group - MarketBeat
Goldman Sachs cuts Moderna stock rating, slashes target to $51 - Investing.com
Exchange Traded Concepts LLC Grows Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
It took bird flu and dreams of AI-assisted cancer vaccines to cue Moderna’s comeback - Sherwood News
How Is The Market Feeling About Moderna? - Benzinga
RFK Jr. says he is not anti-vaccine (MRNA) - Seeking Alpha
Moderna stock rises following RFK Jr's comments - Investing.com
Moderna stock rises following RFK Jr's comments By Investing.com - Investing.com Australia
The Goldman Sachs Group Lowers Moderna (NASDAQ:MRNA) Price Target to $99.00 - MarketBeat
Influenza Clinical and Non-Clinical Studies, Key Companies, - openPR
Moderna (NASDAQ:MRNA) Price Target Cut to $50.00 by Analysts at Evercore ISI - MarketBeat
Moderna, Pfizer Surge Amid CDC-WHO Split And Bird Flu; RFK Jr. Nomination Looms — A Recipe For The Perfect Storm? - Benzinga
Here's What to Expect From Moderna's Next Earnings Report - Nasdaq
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Here's What To Expect From Moderna's Next Earnings Report - Barchart
Moderna (NASDAQ:MRNA) Price Target Lowered to $50.00 at Evercore ISI - MarketBeat
Bird Flu mRNA Vaccines Remain Work in Progress, 4 Years After Covid-19 - Barron's
Moderna Receives $590M From HHS to Develop Bird Flu Vaccine - Dermatology Advisor
Why Moderna Stock Jumped Over 20% This Week - MSN
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio? - Benzinga
After a Reset Year, Is Moderna Stock Poised for a Comeback? - MSN
3 Things You Need to Know if You Buy Moderna Today - sharewise
15,000 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by Harel Insurance Investments & Financial Services Ltd. - MarketBeat
Moderna Developing Injectable mRNA for Norovirus Diarrhea - substack.com
SG Americas Securities LLC Acquires 56,982 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna Retains Retail Support With European COVID-19 Vaccine Tender Win, Stock Hits 2-Week High - MSN
Moderna secures tender to supply COVID-19 vaccine in EU, Norway, and North Macedonia - MSN
Moderna Yo-Yos After European Officials Ink Supply Deal For Covid Shots - Yahoo! Voices
Sick of the stomach bug? Moderna is making a norovirus vaccine - Global News Toronto
Moderna Secures European Contract For Covid-19 Vaccine - Benzinga
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads - Benzinga
Why I Don’t Believe Larry Ellison’s Moderna Stock Hype - Yahoo Finance
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.05%
4.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):